The development of targeted nanomedicines for cancer therapy has been an utmost focus of
research across different fields including materials science, nanotechnology, biotechnology …

PURPOSE Nivolumab, an anti–programmed death-1 monoclonal antibody, has
demonstrated frequent and durable responses in relapsed/refractory classic Hodgkin …

Classical Hodgkin lymphoma is one of the more frequent lymphomas and is generally
considered a highly curable disease with standard first-line chemotherapy and radiotherapy …

Pembrolizumab, a humanized IgG4 monoclonal antibody targeting programmed death-1
protein, has demonstrated efficacy in relapsed/refractory classical Hodgkin lymphoma (cHL) …

Background Increased-dose bleomycin, etoposide, doxorubicin, cyclophosphamide,
vincristine, procarbazine, and prednisone (BEACOPP escalated) improves progression-free …

The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide
recommendations for the management of adult patients with HL. The NCCN panel meets at …

A multitude of new agents for the treatment of hematologic malignancies has been
introduced over the past decade. Hematologists, infectious disease specialists, stem cell …

Simple Summary Vincristine is a vinca alkaloid naturally occurring in Catharanthus roseus. It
belongs to antimitotic compounds, which arrest the cell cycle via disrupting microtubule …

Abstract Disease Overview Hodgkin lymphoma (HL) is an uncommon B‐cell lymphoid
malignancy affecting 8500 new patients annually and representing approximately 10.2% of …

The marine environment is a rich source of biologically active molecules for the treatment of
human diseases, especially cancer. The adaptation to unique environmental conditions led …